Cargando…

BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors

OBJECTIVES: Little is known regarding the outcomes of systemic treatments in BAP1-altered malignant pleural mesothelioma (MPM). MATERIALS AND METHODS: Forty five patients with MPM [group A: eight MPM patients with BAP1 inactivating mutation/copy number loss (FoundationOne(®) CDx/TEMPUSxT), selected...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dudnik, Elizabeth, Bar, Jair, Moore, Assaf, Gottfried, Teodor, Moskovitz, Mor, Dudnik, Julia, Shochat, Tzippy, Allen, Aaron M., Zer, Alona, Rotem, Ofer, Peled, Nir, Urban, Damien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987904/ https://www.ncbi.nlm.nih.gov/pubmed/33777745 http://dx.doi.org/10.3389/fonc.2021.603223

Ejemplares similares

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2(nd)/3(rd)-Generation ALK Tyrosine Kinase Inhibitors (TKIs)
por: Raphael, Ari, et al.
Publicado: (2022)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

Intensity‐modulated radiotherapy is a safe and effective treatment for localized malignant pleural mesothelioma
por: Simon, Michael, et al.
Publicado: (2018)

Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC
por: Gal, Omer, et al.
Publicado: (2020)

Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?
por: Sternschuss, Michal, et al.
Publicado: (2020)

Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study
por: Icht, Oded, et al.
Publicado: (2023)

BRCA mutations detected by tumour next-generation sequencing in non-small cell lung cancer: impact on response to therapy and disease course
por: Tschernichovsky, Roi, et al.
Publicado: (2023)

Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer
por: Landman, Yosef, et al.
Publicado: (2021)

Correlations between pathogenic variants in DNA repair genes and anticancer treatment efficacy in stage IV non‐small cell lung cancer: A large real‐world cohort and review of the literature
por: Averbuch, Itamar, et al.
Publicado: (2023)

Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival
por: Suidan, Anna May, et al.
Publicado: (2019)

Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma
por: Vormoor, Britta, et al.
Publicado: (2014)

Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report
por: Sarfaty, Michal, et al.
Publicado: (2017)

Loss of amplified genes by poly(ADP-ribose) polymerase inhibitors.
por: Nagao, M, et al.
Publicado: (1991)

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer
por: Markman, Maurie
Publicado: (2018)

The Ups and Downs of Tannins as Inhibitors of Poly(ADP-Ribose)glycohydrolase
por: Blenn, Christian, et al.
Publicado: (2011)

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
por: Jannetti, Stephen A., et al.
Publicado: (2020)

Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents
por: Matanes, Emad, et al.
Publicado: (2021)

Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Primary Lung Cancer in Recipients of Lung Transplant
por: Moore, Assaf, et al.
Publicado: (2020)

Poly(ADP-ribose) polymerase inhibitor development: are we in the right direction?
por: Plummer, R
Publicado: (2011)

The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2016)

Current status of poly(ADP-ribose) polymerase inhibitors and future directions
por: Ohmoto, Akihiro, et al.
Publicado: (2017)

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
por: Boussios, Stergios, et al.
Publicado: (2020)

Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy
por: Singh, Bijay, et al.
Publicado: (2020)

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer
por: Dong, Ruihong, et al.
Publicado: (2023)

Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) – Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy
por: Harrision, Daniel, et al.
Publicado: (2020)

Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer
por: Zhang, Jingsong
Publicado: (2014)

Antidepressant-Like Actions of Inhibitors of Poly(ADP-Ribose) Polymerase in Rodent Models
por: Ordway, Gregory A, et al.
Publicado: (2017)

Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers
por: Hastak, Kedar, et al.
Publicado: (2017)

Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide
por: Badawy, Abdulla A.-B.
Publicado: (2020)

Effective natural inhibitors targeting poly ADP-ribose polymerase by computational study
por: Zhong, Sheng, et al.
Publicado: (2021)

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
por: Inderjeeth, Andrisha-Jade, et al.
Publicado: (2022)

Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers
por: Daher, Sameh, et al.
Publicado: (2021)

Long term follow-up of EGFR mutated NSCLC cases
por: Rennert, Gad, et al.
Publicado: (2020)

The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors
por: De Soto, Joseph A., et al.
Publicado: (2006)

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
por: Faraoni, Isabella, et al.
Publicado: (2018)

Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes
por: Faraoni, Isabella, et al.
Publicado: (2019)

Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
por: Madariaga, Ainhoa, et al.
Publicado: (2020)

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
por: Xu, Qin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6phmn8hd9p35eb181ski2j0db9